Literature DB >> 649995

Cefamandole in treatment of peritonitis.

H H Stone, B S Guest, C E Geheber, L D Kolb.   

Abstract

Cefamandole was evaluated as the sole antimicrobial agent used to treat bacterial peritonitis in 113 patients. Dosage varied between 1 and 2 g given intravenously every 6 hr. Laparotomy for excision of infected or gangrenous tissues, closure of gastrointestinal perforations, or drainage of an established abscess was required in 99 of the cases. A good clinical response was obtained in 107 patients, or 95% of the total group. Of the six deaths only one could be attributed to infection. No evidence of renal, hepatic, or hematopoietic toxicity was noted. There were no allergic reactions, although 13 patients (12%) developed phlebitis in a vein used for antibiotic administration. Bacteriological studies revealed aerobic peritonitis in 99% of the patients, with anaerobe participation in 60% of these cases. Sensitivity testing by the disk diffusion and tube dilution methods confirmed the appropriateness of cefamandole therapy; 91% of the gram-negative rods and 61% of the anaerobes were susceptible. From results of this study, it would appear that cefamandole is a reliably effective antibiotic for use in treatment of most forms of acute peritonitis. Its role in surgical prophylaxis may be even more promising.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 649995     DOI: 10.1093/infdis/137.supplement.s103

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  7 in total

1.  Radical peritoneal debridement for established peritonitis. The results of a prospective randomized clinical trial.

Authors:  H C Polk; D E Fry
Journal:  Ann Surg       Date:  1980-09       Impact factor: 12.969

2.  Clinical comparison of antibiotic combinations in the treatment of peritonitis and related mixed aerobic-anaerobic surgical sepsis.

Authors:  H H Stone; T C Fabian
Journal:  World J Surg       Date:  1980-07       Impact factor: 3.352

3.  Perioperative antibiotic therapy for penetrating injuries of the abdomen.

Authors:  L O Gentry; D V Feliciano; A S Lea; H D Short; K L Mattox; G L Jordan
Journal:  Ann Surg       Date:  1984-11       Impact factor: 12.969

Review 4.  Antibiotic trials in intra-abdominal infections. A critical evaluation of study design and outcome reporting.

Authors:  J S Solomkin; J L Meakins; M D Allo; E P Dellinger; R L Simmons
Journal:  Ann Surg       Date:  1984-07       Impact factor: 12.969

5.  Pharmacology, Safety, and efficacy of cefamandole in childhood infections.

Authors:  M C Thirumoorthi; A S Dajani; C V Vincent; M J Maurer
Journal:  Antimicrob Agents Chemother       Date:  1981-07       Impact factor: 5.191

6.  Cefamandole therapy in anaerobic infections.

Authors:  R N Greenberg; M C Scalcini; C V Sanders; A C Lewis
Journal:  Antimicrob Agents Chemother       Date:  1979-03       Impact factor: 5.191

7.  Disposition kinetics of cefamandole during continuous ambulatory peritoneal dialysis.

Authors:  M Bliss; M Mayersohn; T Arnold; J Logan; U F Michael; W Jones
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.